Genetic Study Suggests Omega-3 May Lower Multiple Myeloma Risk Through a Fat-Metabolism Pathway
This study used a genetics-based method called Mendelian randomization to examine whether omega-3 fatty acids are linked to the risk of developing multiple myeloma, a type of blood cancer. Instead of tracking people over time, researchers analyzed genetic data from large population studies to see if genetic variants associated with higher omega-3 levels were also associated with lower cancer risk.
Using data from four separate genetic databases and combining the results in a meta-analysis, the researchers found that genetically predicted higher omega-3 levels were associated with an approximately 20% lower risk of multiple myeloma. Three of the four datasets showed a similar pattern, while one showed no clear association.
The researchers also looked at whether specific blood fats, including phosphatidylcholine (a type of phospholipid), might explain part of this relationship. Their analysis suggested that phosphatidylcholine could act as a mediator, meaning omega-3’s association with lower myeloma risk may partly work through its effects on this particular lipid.
What this means for you
This genetic analysis adds to earlier observational research suggesting a possible link between omega-3 intake and lower cancer risk, and points to phosphatidylcholine as one possible biological pathway involved. However, Mendelian randomization studies have limitations and cannot prove cause and effect on their own, so these findings should be viewed as a starting point for further research rather than dietary or health advice.
Ready to start? The ALP Protocol delivers the EPA & DHA doses used in the research.
Start the ALP ProtocolThis summary is for educational purposes only and is not medical advice. Always talk to your healthcare provider before making changes to your supplement routine.